Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is among the 13 Best Debt Free Dividend Stocks to Buy Now. Morgan Stanley raised its price target on REGN to $768 and expects policy concerns to ease in 2026, shifting focus to company fundamentals. The Ministry of Health in Japan granted marketing approval for Dupixent for children 6-11 with severe asthma. Dupilumab is jointly developed by Sanofi and REGN, studied in over 60 trials for chronic conditions linked to type 2 inflammation. REGN focuses on discovering, developing, and commercializing medicines for serious diseases.

Read more at Yahoo Finance: Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN)